language-icon Old Web
English
Sign In
Acemap > Paper > P993 EASL AND MRECIST RESPONSE TO COMBINATION THERAPY OF SORAFENIB AND TRANSARTERIAL CHEMOEMBOLIZATION PREDICTS SURVIVAL IN HEPATOCELLULAR CARCINOMA

P993 EASL AND MRECIST RESPONSE TO COMBINATION THERAPY OF SORAFENIB AND TRANSARTERIAL CHEMOEMBOLIZATION PREDICTS SURVIVAL IN HEPATOCELLULAR CARCINOMA

2014 
Keywords:
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []
    logo
    • CCF Conference Analysis
    • Map Galaxy
    • What's New
    © Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.